VEGF Polymorphisms Related to Higher Serum Levels of Protein Identify Patients with Hepatocellular Carcinoma
Table 3
Allelic and genotypic frequencies of VEGF-C936T and VEGF-A1154G polymorphisms in patients with hepatocellular carcinoma (G1), considering the BCLC clinical classification.
(a) C936T
VEGF
BCLC: 89 patients
value
A ()
B/C ()
D ()
A × B/C
A × D
B/C × D
Allele
AF
AF
AF
C
48
0.86
88
0.85
16
0.89
1.000
1.000
1.000
T
8
0.14
16
0.15
2
0.11
Genotype
(%)
(%)
(%)
C/C
20
(71)
36
(69)
7
(78)
1.000
1.000
0.7131
C/T
8
(29)
16
(31)
2
(22)
T/T
0
(0)
0
(0)
0
(0)
—
—
—
(b) A1154
VEGF
BCLC: 89 patients
value
A ()
B/C ()
D ()
A × B/C
A × D
B/C × D
Allele
n
AF
n
AF
n
AF
G
41
0.73
83
0.80
14
0.78
0.4508
1.000
0.7623
A
15
0.27
21
0.20
4
0.22
Genotype
(%)
(%)
(%)
G/G
14
(50)
35
(67)
5
(56)
0.2023
1.000
0.7056
A/G
13
(46)
13
(25)
4
(44)
0.0888
1.000
0.2489
A/A
1
(4)
4
(8)
0
(0)
0.6525
—
—
Fisher’s exact test or Chi-Square test with Yates correction; BCLC = Barcelona Clinic Liver Cancer; VEGF = vascular endothelial growth factor; = number of subjects; = number of alleles; AF = absolute frequency.
